Want to see YDES full AI Analyst Report?
YDES Stock Chart & Stats
$3.54
--
Market closed
$3.54
--
Day’s Range― - ―
52-Week Range$1.70 - $22.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)230.56K
Market Cap
$279.83M
Enterprise Value$156.71
Total Cash (Recent Filing)$6.31K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.13
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding70,842,840
10 Day Avg. Volume556,543
30 Day Avg. Volume230,561
Financial Highlights & Ratios
PEG Ratio1.29
Price to Book (P/B)-284.80
Price to Sales (P/S)1362.74
P/FCF Ratio-101.20
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Equity PositionThe return to positive shareholders’ equity materially improves the company’s capital position and may reduce near-term balance-sheet pressure. If sustained, it can strengthen creditor confidence, support continued operations, and lessen the immediate need for recapitalization while the business develops.
Strong Interim Revenue GrowthMore than fourfold year-over-year revenue growth indicates expanding commercial activity and improving market traction. Sustained growth would provide a larger base over which to spread operating costs, support investment in the platform, and improve the eventual path toward scalable economics.
Physician-led Nutraceutical PlatformThe physician-partnership model could create trusted distribution and recurring consumer-health revenue while connecting nutraceutical products with diagnostics and clinical services. This ecosystem approach offers a potentially scalable route to broaden customer relationships beyond a single product.
Bears Say
Persistent Operating LossesOperating losses despite higher revenue show that current commercial growth is not yet translating into earnings. Unless revenue expands faster than expenses or spending becomes more efficient, continued losses will constrain reinvestment capacity and weaken the durability of the business model.
Accelerating Cash BurnPersistent cash outflows mean the company cannot currently fund operations through internally generated cash. Continued burn increases reliance on external financing, leaves less flexibility to pursue growth initiatives, and raises liquidity risk if funding conditions or investor support weaken.
Weak Earnings QualityNegative gross profit and deeply negative operating margins indicate that the core offering has not yet demonstrated sustainable unit economics. This limits confidence that revenue growth alone will produce operating leverage and makes a durable recovery dependent on major improvement in costs or pricing.
YD Bio Limited News
YDES FAQ
What was YD Bio Limited’s price range in the past 12 months?
YD Bio Limited lowest stock price was $1.70 and its highest was $22.00 in the past 12 months.
What is YD Bio Limited’s market cap?
YD Bio Limited’s market cap is $279.83M.
When is YD Bio Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were YD Bio Limited’s earnings last quarter?
Currently, no data Available
Is YD Bio Limited overvalued?
According to Wall Street analysts YD Bio Limited’s price is currently Overvalued.
Does YD Bio Limited pay dividends?
YD Bio Limited does not currently pay dividends.
What is YD Bio Limited’s EPS estimate?
YD Bio Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does YD Bio Limited have?
YD Bio Limited has 70,842,840 shares outstanding.
What happened to YD Bio Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of YD Bio Limited?
Currently, no hedge funds are holding shares in YDES
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
YD Bio Limited Stock Smart Score
Company Description
YD Bio Limited
Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.
Technical Analysis
Scinai Immunotherapeutics
―
Aditxt
―
SciSparc Ltd.
―
CDT Equity
―
Virax Biolabs Group Ltd. Class A
―
Ownership Overview
76.84% Insiders
0.06% Mutual Funds
0.17% Other Institutional Investors
22.91% Public Companies and
Individual Investors